more featured news
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric.
DNB//Back Bay is pleased to sponsor the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.
This two-day equity conference is by invitation to institutional healthcare specialist and generalist investors, industry experts, corporate development, and healthcare executives. The NAHC includes sector-specific panel discussions with insights from DNB healthcare equity analysts, industry leaders, and investors.
featured transactions









Diversity Within Our Walls and Across Our Community
Back Bay is built on an appreciation of unique perspectives, a passion for creative approaches, and the ability to listen.